ARO-C3 + Placebo
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
C3 Glomerulopathy
Conditions
C3 Glomerulopathy, IgA Nephropathy
Trial Timeline
Feb 1, 2022 → Oct 31, 2025
NCT ID
NCT05083364About ARO-C3 + Placebo
ARO-C3 + Placebo is a phase 1/2 stage product being developed by Arrowhead Pharmaceuticals for C3 Glomerulopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT05083364. Target conditions include C3 Glomerulopathy, IgA Nephropathy.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05083364 | Phase 1/2 | Completed |
Competing Products
5 competing products in C3 Glomerulopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Iptacopan | Novartis | Pre-clinical | 23 |
| LNP023 | Novartis | Phase 3 | 77 |
| Avacopan + Avacopan Matching Placebo | Amgen | Phase 2 | 51 |
| BCX9930 | BioCryst Pharmaceuticals | Phase 2 | 47 |
| OMS906 study drug | Omeros Corporation | Phase 2 | 47 |